(VIANEWS) – Origin Bancorp (OBNK), DexCom (DXCM), EVO Payments (EVOP) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Origin Bancorp (OBNK)
35.6% sales growth and 10.44% return on equity
Origin Bancorp, Inc. operates as a bank holding company for Origin Bank that provides banking and financial services to small and medium-sized businesses, municipalities, high net worth individuals, and retail clients in Louisiana, Texas, and Mississippi. It offers noninterest and interest-bearing checking accounts, savings deposits, money market accounts, and time deposits; and offers commercial real estate, construction/land development, consumer, residential real estate, commercial and industrial, mortgage warehouse, residential mortgage, and paycheck protection program loans. The company also offers personal and commercial property, and casualty insurance products; and Internet banking and voice response information, mobile applications, cash management, overdraft protection, direct deposit, safe deposit box, U.S. savings bonds, and automatic account transfer services; and treasury management, mortgage origination and servicing facilities, peer-to-peer electronic pay solutions, and personal financial management solutions. As of December 31, 2020, it operated 43 banking centers. The company was founded in 1912 and is headquartered in Ruston, Louisiana.
Earnings Per Share
As for profitability, Origin Bancorp has a trailing twelve months EPS of $3.26.
PE Ratio
Origin Bancorp has a trailing twelve months price to earnings ratio of 11.44. Meaning, the purchaser of the share is investing $11.44 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.44%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 27.2%, now sitting on 307.86M for the twelve trailing months.
2. DexCom (DXCM)
19.2% sales growth and 9.19% return on equity
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, DexCom has a trailing twelve months EPS of $5.2.
PE Ratio
DexCom has a trailing twelve months price to earnings ratio of 22.6. Meaning, the purchaser of the share is investing $22.6 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.19%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 87.5% and 29.4%, respectively.
3. EVO Payments (EVOP)
13.9% sales growth and 4.42% return on equity
EVO Payments, Inc. operates as an integrated merchant acquirer and payment processor in the Americas and Europe. Its payment and commerce solutions consist of gateway solutions, online fraud prevention and management reporting, online hosted payments page capabilities, cellphone-based SMS integrated payment collection services, security tokenization and encryption solutions at the point-of-sale, dynamic currency conversion, ACH, loyalty offers, and other ancillary solutions. The company also offers processing capabilities for specific industries and provides merchants with recurring billing, multi-currency authorization and settlement, and cross-border processing. In addition, it provides other services that enable through technical integrations with third-party providers. The company offers its services to approximately 550,000 merchants. EVO Payments, Inc. was founded in 1989 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, EVO Payments has a trailing twelve months EPS of $-0.11.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.42%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5%, now sitting on 543.08M for the twelve trailing months.
Sales Growth
EVO Payments’s sales growth is 5% for the ongoing quarter and 13.9% for the next.
4. BioMarin Pharmaceutical (BMRN)
12.9% sales growth and 3.19% return on equity
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Earnings Per Share
As for profitability, BioMarin Pharmaceutical has a trailing twelve months EPS of $0.72.
PE Ratio
BioMarin Pharmaceutical has a trailing twelve months price to earnings ratio of 125.35. Meaning, the purchaser of the share is investing $125.35 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.19%.
Volume
Today’s last reported volume for BioMarin Pharmaceutical is 1467930 which is 3.35% below its average volume of 1518930.
Moving Average
BioMarin Pharmaceutical’s worth is way under its 50-day moving average of $106.66 and under its 200-day moving average of $93.60.
Yearly Top and Bottom Value
BioMarin Pharmaceutical’s stock is valued at $90.25 at 20:22 EST, way below its 52-week high of $117.77 and way above its 52-week low of $70.73.
5. Intuitive Surgical (ISRG)
11.7% sales growth and 11.66% return on equity
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Earnings Per Share
As for profitability, Intuitive Surgical has a trailing twelve months EPS of $9.72.
PE Ratio
Intuitive Surgical has a trailing twelve months price to earnings ratio of 25.21. Meaning, the purchaser of the share is investing $25.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.66%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 6.2% and 14.9%, respectively.
Sales Growth
Intuitive Surgical’s sales growth is 6.8% for the current quarter and 11.7% for the next.
Yearly Top and Bottom Value
Intuitive Surgical’s stock is valued at $245.04 at 20:22 EST, way under its 52-week high of $308.97 and way higher than its 52-week low of $180.07.
Moving Average
Intuitive Surgical’s worth is higher than its 50-day moving average of $245.00 and higher than its 200-day moving average of $231.07.
6. Huron Consulting Group (HURN)
9.9% sales growth and 13.44% return on equity
Huron Consulting Group Inc., a professional services firm, provides consultancy services in the United States and internationally. Its Healthcare segment provides advisory services in the areas of financial and operational improvement, care transformation, and revenue cycle managed services; organizational transformation; and digital, technology and analytic solutions to national and regional hospitals, integrated health systems, academic medical centers, community hospitals, and medical groups. The company's Business Advisory segment offers cloud-based technology, analytics, restructuring, and capital advisory solutions to life science, financial, healthcare, education, energy and utilities, and industrials and manufacturing industries, as well as to public sectors. Its Education segment provides research enterprise and student lifecycle; digital, technology and analytic solutions; and organizational transformation services to public and private colleges and universities, academic medical centers, research institutes, and other not-for-profit organizations. Huron Consulting Group Inc. was incorporated in 2002 and is headquartered in Chicago, Illinois.
Earnings Per Share
As for profitability, Huron Consulting Group has a trailing twelve months EPS of $3.67.
PE Ratio
Huron Consulting Group has a trailing twelve months price to earnings ratio of 20.58. Meaning, the purchaser of the share is investing $20.58 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.44%.
Sales Growth
Huron Consulting Group’s sales growth is 15.2% for the ongoing quarter and 9.9% for the next.
Moving Average
Huron Consulting Group’s value is above its 50-day moving average of $71.42 and above its 200-day moving average of $69.20.
Yearly Top and Bottom Value
Huron Consulting Group’s stock is valued at $75.54 at 20:22 EST, under its 52-week high of $82.87 and way higher than its 52-week low of $43.43.
7. Regional Management Corp. (RM)
9.5% sales growth and 23.76% return on equity
Regional Management Corp., a diversified consumer finance company, provides various installment loan products primarily to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It offers small and large installment loans; retail loans to finance the purchase of furniture, appliances, and other retail products; insurance products, including credit life, credit accident and health, credit property, vehicle single interest, and credit involuntary unemployment insurance; collateral protection insurance; and property insurance, as well as reinsurance products. The company's loans are sourced through branches, direct mail campaigns, digital partners, and retailers, as well as its consumer website. As of March 26, 2020, it operated through a network of 366 branches in 11 states located in the Southeastern, Southwestern, Mid-Atlantic, and Midwestern United States. Regional Management Corp. was founded in 1987 and is headquartered in Greer, South Carolina.
Earnings Per Share
As for profitability, Regional Management Corp. has a trailing twelve months EPS of $5.28.
PE Ratio
Regional Management Corp. has a trailing twelve months price to earnings ratio of 5.26. Meaning, the purchaser of the share is investing $5.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.76%.
Sales Growth
Regional Management Corp.’s sales growth is 11% for the ongoing quarter and 9.5% for the next.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 44.2% and positive 4.8% for the next.
8. Rollins (ROL)
9.1% sales growth and 30.09% return on equity
Rollins, Inc., through its subsidiaries, provides pest and wildlife control services to residential and commercial customers in the United States and internationally. The company offers pest control services to residential properties protecting from common pests, including rodents, insects, and wildlife. It also provides workplace pest control solutions for customers across various end markets, such as healthcare, foodservice, and logistics. In addition, the company offers traditional and baiting termite protection, as well as ancillary services. It serves clients directly, as well as through franchisee operations. Rollins, Inc. was incorporated in 1948 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, Rollins has a trailing twelve months EPS of $0.63.
PE Ratio
Rollins has a trailing twelve months price to earnings ratio of 58.44. Meaning, the purchaser of the share is investing $58.44 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.09%.
Volume
Today’s last reported volume for Rollins is 247888 which is 81.56% below its average volume of 1344640.
Moving Average
Rollins’s worth is higher than its 50-day moving average of $35.97 and above its 200-day moving average of $36.70.
